Senior Portfolio Manager Martin Cobb warned on BNN Bloomberg that rising U.S. 🇺🇸 national debt ($10T maturing soon plus a $2T annual deficit) and weakening demand for U.S. 🇺🇸 Treasuries pose a major threat to markets via rising bond yields. Because higher yields can squeeze stock valuations, Cobb recommends deploying cash into high-quality, durable healthcare companies with strong cash flows and low sensitivity to debt markets. Here is how CAD and USD investors can position for this market environment: For US 🇺🇸 Dollar Investors (USD) * Direct Stock Picks: Zoetis ($ZTS) for animal health, EssilorLuxottica ($ESLOY) for global optics and wearable tech, and Smith & Nephew ($SNN) for medical devices. * Healthcare & Defensive ETFs: Vanguard Health Care ETF ($VHT) or Health Care Select Sector SPDR Fund ($XLV) for broad sector defense against market shifts. For Canadian 🇨🇦 Dollar Investors (CAD) * Direct Stock Access: Invest directly in Cobb's picks ($ZTS, $SNN, $ESLOY) via USD accounts or CDR equivalents where available. * Healthcare & Defensive ETFs: Harvest Healthcare Leaders Income ETF ($HHL) or iShares Global Healthcare Index ETF ($XHC) to gain Canadian dollar-denominated exposure to resilient global healthcare leaders. Did You Know? 🧐 The U.S. government now spends nearly 20% of all tax revenues just paying interest on its debt! That massive fiscal strain is why seasoned investors like Martin Cobb look for cash-generative healthcare companies that don't rely on borrowing to fund growth. — This post is for educational and informational purposes only and does not constitute financial or investment advice.read more
$OSCR isn’t cheap because it trades like a mature health insurer. It’s cheap because I don’t think the valuation fully reflects how much earlier Oscar is in its growth curve. Oscar does trade at a premium to some peers on sales and forward earnings. But that makes sense. $UNH, $ELV, $HUM and others are already massive, mature businesses growing much slower. Oscar is still scaling rapidly, expanding margins and only beginning to show what earnings could look like at maturity. And even with that growth advantage, $OSCR trades around 9.6x EV/EBITDA, below several of those larger peers. So in a way, Oscar actually is cheap. You’re paying a relatively modest valuation for a company that could still have years of above-industry growth and margin expansion ahead of it. That’s a setup I really like. read more
$OSCR earnings expectations are moving FAST. The consensus estimate for Oscar’s current year earnings has jumped 227.7% over the last 60 days. That’s the kind of revision I pay attention to. The stock moving higher is nice, but analysts having to materially raise their expectations for the actual business is much more important. $OSCR was also added to Zacks’ #1 Strong Buy list today. Still one of my highest conviction turnaround plays.
Compass Pathways: There Are Different Scenarios To Be Considered In Clinical, Regulatory, And Commercialization Aug 25, 2026, 1:42 PM ET $CMPS Summary Compass Pathways plc is rated Strong Buy with a $25–$30 fair value, reflecting a significant upside to current levels. Compass Pathways' COMP360 offers a capacity advantage over Spravato, enabling four times more patients per monitored hour and supporting higher peak sales estimates. Regulatory momentum is strong, but timing risk exists due to DEA rescheduling, which could create interim share price volatility. Key upside catalysts include a two-dose label and permanent reimbursement codes, both of which could materially lift the base case valuation. https://seekingalpha.com/article/4940062-compass-pathways-there-are-different-scenarios-to-be-considered-in-clinical-regulatory-and-commercialization?utmread more
I have always stayed away from small cap Biotech stocks. Mainly because it’s hard and your money is depending on things like clinical tests and medical trials being successful. Much different than a business establishing new products and increasing profit margin. But Biodesix is an interesting one. They specialize in blood based testing for lung disease and lung cancer. Since they cut shares almost a year ago from 156 mil to 8 mil, the stock is reaching new highs. Revenue is up 34% YOY along with expanding gross margin at 82%. Not bad.
